Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE Actual Data of Vomiting Incidence by Chemotherapy Evaluation studyReportar como inadecuado




Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE Actual Data of Vomiting Incidence by Chemotherapy Evaluation study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Supportive Care in Cancer

, Volume 23, Issue 9, pp 2833–2840

First Online: 17 June 2015Received: 12 March 2015Accepted: 08 June 2015DOI: 10.1007-s00520-015-2809-3

Cite this article as: Escobar, Y., Cajaraville, G., Virizuela, J.A. et al. Support Care Cancer 2015 23: 2833. doi:10.1007-s00520-015-2809-3

Abstract

PurposeThis study aims to determine the incidence of nausea and vomiting CINV after moderately emetogenic chemotherapy MEC, under medical practice conditions and the accuracy with which physicians perceive CINV.

MethodsChemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints.

ResultsOf 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 5-HT3 antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea from 9.4 to 21.7 % and vomiting from 9.2 to 16.5 % was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients’ diary.

ConclusionDespite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.

KeywordsChemotherapy-induced nausea and vomiting Moderately emetogenic chemotherapy Complete response Acute and delayed phase Physicians’ perception Yolanda Escobar and Gerardo Cajaraville contributed equally to this work.

Electronic supplementary materialThe online version of this article doi:10.1007-s00520-015-2809-3 contains supplementary material, which is available to authorized users.

An erratum to this article can be found at http:-dx.doi.org-10.1007-s00520-015-2842-2.

Download fulltext PDF



Autor: Yolanda Escobar - Gerardo Cajaraville - Juan Antonio Virizuela - Rosa Álvarez - Andrés Muñoz - Olatz Olariaga - María 

Fuente: https://link.springer.com/







Documentos relacionados